about
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancersParalog-selective Hsp90 inhibitors define tumor-specific regulation of HER2Selective targeting of the stress chaperome as a therapeutic strategyAffinity-based proteomics reveal cancer-specific networks coordinated by Hsp90Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitorsAssay strategies for the discovery and validation of therapeutics targeting Brugia pahangi Hsp90A purine analog synergizes with chloroquine (CQ) by targeting Plasmodium falciparum Hsp90 (PfHsp90)
P50
Q27022514-4C5E4ECE-0F3B-4C95-B1D6-9B867E914196Q27679845-5C454446-907D-449A-962F-91837A2F27BCQ28248791-3FE6F74F-3DB6-40C3-9564-85571B046F49Q28249103-405F4036-4B21-411F-B0EE-F6031136BEECQ28294781-EF60D3B1-E3C0-4CBA-B61D-AB485A55E73EQ28474428-01A56FAE-E593-4D1A-939A-0D8181C00D1BQ28533944-4223A478-8DEF-4B21-8776-CE070099148B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tony Taldone
@ast
Tony Taldone
@en
Tony Taldone
@es
Tony Taldone
@nl
Tony Taldone
@sl
type
label
Tony Taldone
@ast
Tony Taldone
@en
Tony Taldone
@es
Tony Taldone
@nl
Tony Taldone
@sl
prefLabel
Tony Taldone
@ast
Tony Taldone
@en
Tony Taldone
@es
Tony Taldone
@nl
Tony Taldone
@sl